Table 2. Meta-analysis of rs2279115 polymorphism and cancer risk in cancer type.

rs2279115	No.ofstudies	PQ	I2	OR	95% CI	PZ	Model
Cancer type
Hematopoietic cancer	2(333/333)
C vs. A		0.144	53.1%	1.19	0.78,1.81	0.418	Random-effects model
CC+ CA vs. AA		0.586	0.00%	0.99	0.63,1.57	0.978	Fixed-effects model
CC vs. CA+AA		0.130	56.4%	1.40	0.75,2.63	0.296	Random-effects model
CC vs. CA		0.136	54.9%	1.48	0.74,2.82	0.272	Random-effects model
Digestive system cancers	3(1628/1640)
C vs. A		0.610	0.00%	1.31	1.18,1.45	<0.001	Fixed-effects model
CC+ CA vs. AA		0.371	0.00%	1.30	1.07,1.58	0.008	Fixed-effects model
CC vs. CA+AA		0.756	0.00%	1.51	1.31,1.74	<0.001	Fixed-effects model
CC vs. CA		0.701	0.00%	1.47	1.27,1.72	<0.001	Fixed-effects model
Endocrine system cancer	2(210/435)
C vs. A		0.203	38.3%	1.34	1.06,1.71	0.016	Fixed-effects model
CC+ CA vs. AA		0.045	75.1%	1.45	0.57,3.71	0.439	Random-effects model
CC vs. CA+AA		0.649	0.00%	1.49	1.06,2.09	0.023	Fixed-effects model
CC vs. CA		0.856	0.00%	1.42	0.99,2.04	0.058	Fixed-effects model
Breast Cancer	4(1470/1628)
C vs. A		0.082	55.3%	1.05	0.87,1.28	0.599	Random-effects model
CC+ CA vs. AA		0.005	76.5%	1.16	0.69,1.96	0.577	Random-effects model
CC vs. CA+AA		0.574	0.00%	1.07	0.92,1.25	0.374	Fixed-effects model
CC vs. CA		0.893	0.00%	1.03	0.87,1.21	0.742	Fixed-effects model
Respiratory cancer	3(1537/2057)
C vs. A		0.000	92.6%	1.32	0.89,1.97	0.170	Random-effects model
CC+ CA vs. AA		0.001	84.7%	1.46	0.82,2.58	0.198	Random-effects model
CC vs. CA+AA		0.000	91.6%	1.45	0.86,2.46	0.163	Random-effects model
CC vs. CA		0.000	86.9%	1.37	0.88,2.14	0.163	Random-effects model